BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for 2006. For the three months ended December 31, 2006, Enzon reported a net loss of $13.6 million or $(.31) per diluted share, as compared to a net loss of $285.6 million or $(6.56) per diluted share for the fourth quarter of 2005. For the full year ended December 31, 2006, Enzon reported net income of $21.3 million or $.46 per diluted share, compared to a net loss of $380.0 million or $(8.73) per diluted share for the full year ended December 31, 2005. The Company’s financial results in 2005 were significantly impacted by unusual charges associated with the impairment of intangible assets, goodwill, and deferred tax assets.
